OR WAIT null SECS
January 10, 2022
The collaboration will leverage Alynlam’s proprietary small interfering RNA (siRNA) technology to inhibit a target discovered by Novartis.
January 07, 2022
Neurimmune will receive up to $760 million for NI006, an investigational human monoclonal antibody in development for the treatment of transthyretin amyloid cardiomyopathy.
The acquisition of Protein Metrics expands Insightful Science’s R&D solutions to include proteomics.
December 23, 2021
Sanofi’s acquisition of Amunix will grant access to their promising immuno-oncology pipeline.
December 17, 2021
Bionique Testing Laboratories has been acquired by Asahi Kasei Medical and will join the company’s biosafety testing services unit.
December 15, 2021
Pfizer’s $6.7 billion acquisition of Arena will give them access to a portfolio of immuno-inflammatory therapies.
GlaxoSmithKline, together with the University of Oxford, has launched the Oxford-GSK Institute under a new collaboration that aims to study complex diseases to accelerate the success of drug discovery and drug development efforts.
December 09, 2021
Lonza has signed a five-year services agreement to provide for the development and manufacturing of biologics and small molecules for portfolio companies owned by Bioqube Ventures.
Leucid Bio will collaborate with Lonza to use Lonza’s Cocoon Platform for clinical and commercial manufacturing of CAR T cells for Leucid’s lead candidate.
Sanofi’s acquisition of Origimm Biotechnology will add to its pipeline of vaccine candidates for treating acne.